Highlights Despite advanced treatment, relapse has been reported in multiple sclerosis (MS) patients. T cell targeted therapies, commonly used in MS treatment, have safety issues. Ublituximab, a drug targetting B cells, was found to have promising results in lowering MS relapse rates. Here's a Journal Watch that discusses the study “Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis” from The New England Journal of Medicine, 2022.
Over the last decade, understanding the role of B and T cells in an autoimmune disease like multiple sclerosis has been probed in both pre-clinical and clinical research. Ublituximab (TG-1101) is a novel, third-generation, chimeric, monoclonal antibody that binds to the trans-membrane antigen CD20 of the B-lymphocytes. In this phase III study, ublituximab was found to lower the annualized relapse of MS with fewer brain lesions than…
